RNA polymerase variants and uses thereof

By mutating amino acid sequences to T7 RNA polymerase into variant RNA polymerase, the problems of low capping rate and high production cost in the prior art are solved, and an efficient and economical mRNA capping process is achieved, and the quality of the product is improved. and security.

CN118931872AActive Publication Date: 2024-11-12NANJING VAZYME BIOTECH CO LTD

Patent Information

Application Number
CN202411429549.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-14
Publication Date
2024-11-12
Estimated Expiration
2044-10-14

AI Technical Summary

Technical Problem

The existing RNA polymerases have a low capping rate during in vitro transcription, require wild-type promoter replacement, and have impurities problems, resulting in high production costs and safety concerns.

Method used

By performing specific mutations of the amino acid sequence of T7 RNA polymerase, variant RNA polymerase is formed, which improves its catalytic efficiency, reduces dependence on wild-type promoters, and improves the yield and purity of capped mRNA by optimizing in vitro transcription reaction conditions.

Benefits of technology

It significantly improves the mRNA capping rate, reduces the amount of hat analog, reduces production costs, and improves the integrity and safety of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931872A_ABST
    Figure CN118931872A_ABST
Patent Text Reader

Abstract

The invention provides a T7 RNA polymerase variant and application thereof, the amino acid sequence of the T7 RNA polymerase variant comprises substitution or deletion of at least one of the following amino acid sites relative to SEQ ID NO: 1: R34, K172, Y178, R386, D388, Q435, N437 and D438. Compared with wild type T7 RNA polymerase, the variant has improved catalytic activity, and can improve the capping rate of mRNA products in the in vitro transcription (co-transcription capping) process. In addition, the invention also provides a method for preparing RNA by using the variant, and more capped mRNA can be obtained by adopting the method for preparing RNA molecules.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biotechnology, and in particular to RNA polymerase variants, preparation methods thereof, and applications thereof in RNA synthesis. Background Art

[0002] The 5' end of the complete mRNA of eukaryotic organisms has a 7-methylguanosine (m7G) cap, which is formed in vivo by RNA triphosphatase, mRNA guanosine transferase, mRNA methyltransferase, and mRNA nucleoside 2'-oxymethyltransferase. The 5' cap structure is involved in preventing mRNA from being degraded by nuclease exonucleases, reducing mRNA immunogenicity, regulating mRNA half-life, and regulating translation. In the process of preparing mRNA by in vitro transcription (IVT), researchers usually add cap analogs during the preparation process to simulate the 5' cap structure of eukaryotic cell mRNA.

[0003] The cap structure at the 5' end of mRNA has a significant impact on the stability, translation efficiency and immunogenicity of mRNA. With the continuous deepening of research, the importance of cap analogs has become increasingly prominent. For this reason, people continue to develop new cap analogs for use in mRNA vaccines and therapeutic RNA. Today, cap analogs have developed to the third generation. The first generation of cap analogs has two free 3'-OH groups, which causes the cap analogs to be reversely incorporated. Therefore, the first generation of cap analogs are rarely seen on the market; the second generation ARCA cap analogs (Formula 1) and the third generation cap analogs (Formula 2) are common on the market. Their main structural formulas are shown as examples:

[0004] Formula 1

[0005] Formula 2

[0006] ARCA cap analog is a modified cap analog, whose 3'-OH group near m7G is replaced by -OCH3. Due to this replacement, RNA polymerase can only use the remaining hydroxyl group to initiate transcription, forcing ARCA cap to be incorporated in the forward direction. The third generation cap analog, such as CleanCap AG, can form a Cap 1 structure, which has a significantly improved capping rate compared to the second generation cap analog, but the wild-type promoter needs to be replaced from the original 5'-TAATACGACTCACTATAGG -3' to 5'-TAATACGACTCACTATAAG -3'. Whether the replacement of the promoter will bring safety problems and the generation of new impurities remains to be proven. If the wild-type promoter is used, the capping rate is still low, and the RNA product that is not successfully capped not only causes a waste of raw materials, but also needs to be removed by column purification in the later stage, which increases the production cost. Therefore, if the utilization rate of the cap analog can be improved by modifying the T7 RNA polymerase, without the need to replace the wild-type promoter, it is of great significance in the economical production of mRNA and drug safety. Summary of the invention SUMMARY OF THE INVENTION

[0008] In a first aspect, the present application provides a class of RNA polymerase variants, whose amino acid sequence comprises a mutation of at least one amino acid selected from R34, K172, Y178, R386, D388, Q435, N437 or D438 relative to SEQ ID NO: 1, and the mutation type can be selected from substitution or deletion.

[0009] In a second aspect, the present application provides one or more biological materials selected from the following: 1) a polynucleotide molecule encoding an RNA polymerase variant; 2) an expression vector comprising the polynucleotide molecule as described in 1); 3) A host cell comprising the polynucleotide molecule described in 1), or a host cell comprising the expression vector described in 2).

[0010] In a third aspect, the present application provides a method for preparing the above-mentioned RNA polymerase variant.

[0011] In a fourth aspect, the present application provides a composition comprising at least one RNA polymerase variant as described in the present application.

[0012] In a fifth aspect, the present application provides a kit comprising at least one RNA polymerase variant as described in the present application.

[0013] In a sixth aspect, the present application also provides the use of the above-mentioned RNA polymerase variants, compositions or kits in in vitro transcription.

[0014] In a seventh aspect, the present application also provides a method for preparing RNA or capped RNA. DETAILED DESCRIPTION OF THE INVENTION

[0016] RNA polymerase variants

[0017] The RNA polymerase variant provided in the present application is a bacteriophage T7 RNA polymerase (T7 RNAP) variant, and the amino acid sequence of the variant comprises at least one mutation selected from the following amino acid sites relative to SEQ ID NO: 1: R34, K172, Y178, R386, D388, Q435, N437 or D438, and the mutation type is selected from substitution or deletion.

[0018] In some embodiments, the variant has an A substitution at position R34.

[0019] In some embodiments, the mutation type of the variant at the K172 site is a deletion.

[0020] In some embodiments, the substitution at position Y178 of the variant can be selected from: H or D.

[0021] In some embodiments, the variant may have a substitution at position R386 selected from: C, W, M, A, I or F.

[0022] In some embodiments, the variant has a K substitution at position D388.

[0023] In some embodiments, the variant may have a substitution at position Q435 selected from: A, H or T.

[0024] In some embodiments, the variant may have a substitution at position N437 selected from: F or T.

[0025] In some embodiments, the variant may have a substitution at position D438 selected from: T, L, I, P or V.

[0026] In some embodiments, the amino acid sequence of the variant comprises any of the following substitutions or substitution groups compared to SEQ ID NO: 1: R386W, R386C, D388K, Q435H, Q435T, Q435A, N437F, N437T, D438T, D438L, D438I, D438P, D438V, R386A+R34A, R386M+R34A, R386M+Y178H, R386W+N437T, R386I+del-K172, R386F+Y178D, R386C+D438P, or D388K+D438P.

[0027] In some embodiments, the RNA polymerase variant provided herein has an amino acid sequence having at least 97%, at least 98%, at least 99% or higher sequence identity compared to the sequence shown in any one of SEQ ID NOs: 2-22. In some embodiments, the amino acid sequence of the variant is as shown in any one of SEQ ID NOs: 2-22.

[0028] Polynucleotide molecules

[0029] The polynucleotide molecules provided by the present application encode any RNA polymerase variant described in the present application. In some embodiments, the polynucleotide molecules are shown in any one of SEQ ID NOs: 23-44.

[0030] Among them, the polynucleotide molecules described in the present application may have various modifications in the coding region, as long as the variant amino acid sequence of the present application does not change with the degeneracy of the codons or does not change with the preferred codons in the organism expressing the variant.

[0031] Expression vector

[0032] The expression vector provided in the present application refers to a linear or circular DNA molecule, which generally contains elements such as a multiple cloning site, a resistance gene, a replication origin site, etc. In some embodiments, the expression vector described in the present application is pQE-80L.

[0033] In some embodiments, the vector described in the present application comprises a polynucleotide molecule encoding the RNA polymerase variant of the present application. In some embodiments, further, the vector also comprises one or more regulatory sequences (such as enhancer, promoter and terminator sequences, etc.), which are operably connected to the polynucleotide molecule encoding the variant.

[0034] Host cells

[0035] The host cell provided in the present application can be any cell that is beneficial to the expression of the variant of the present application, that is, any cell that is susceptible to transformation, transfection or transduction containing the expression vector of the present application, including any cell progeny that is different from the parent cell due to mutations occurring during replication.

[0036] In some embodiments, the host cell described in the present application comprises the above-mentioned polynucleotide molecule or the expression vector.

[0037] In some embodiments, the host cell is a prokaryotic cell, which can be selected from gram-positive bacteria or gram-negative bacteria. In some embodiments, the host cell is a gram-positive bacteria, including but not limited to: Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus and Streptomyces. In some embodiments, the host cell is a gram-negative bacteria, including but not limited to: Campylobacter, Escherichia coli, Flavobacterium, Fusobacterium, Helicobacter, Silene Bacillus, Neisseria, Pseudomonas, Salmonella and Ureaplasma.

[0038] Method for preparing variants

[0039] The present application provides a method for preparing the above-mentioned RNA polymerase variant, comprising: (1) culturing the host cell described in the present application under conditions suitable for the expression of the variant; and (2) recovering the variant.

[0040] In some embodiments, the method for recovering the variant can be a method well known in the art, such as centrifugation, filtration, treatment with a crystal protein precipitant (salting out), extraction, ultrasonication, ultrafiltration, dialysis, various chromatography methods such as molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, etc., HPLC, and combinations of the above methods.

[0041] In some embodiments, the preparation method further includes a step of purifying the variant, and the purification step can be a method well known in the art, such as chromatography (such as ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography), ammonium sulfate precipitation, etc.

[0042] Composition

[0043] The present application provides a composition comprising at least one RNA polymerase variant described in the present application.

[0044] The composition described in the present application may be a composition for storing RNA polymerase variants. In some embodiments, the composition described in the present application may optionally include, in addition to the above-mentioned RNA polymerase variants: buffer components (such as Tris base, Tris-HCl, HEPES, MOPS), salts (such as NaCl), enzyme inhibitors (such as EDTA), reducing agents (such as DTT), surfactants (such as TritonX-100), stabilizers (such as glycerol) and other components. In some embodiments, the composition for storing RNA polymerase variants described in the present application includes: RNA polymerase variants, Tris-HCl, NaCl, EDTA, DTT, Triton X-100 and glycerol.

[0045] The composition of the present application can also be an in vitro transcription reaction composition. In some embodiments, the composition, in addition to the above-mentioned RNA polymerase variant, also includes one or more in vitro transcription reaction reagents (such as: buffer components, modified or unmodified nucleoside triphosphates, RNA enzyme inhibitors, pyrophosphatase, magnesium ions, water, etc.). In some embodiments, the composition also includes a DNA template. In some embodiments, the composition also includes a cap analog.

[0046] In some embodiments, the in vitro transcription reaction composition described in the present application comprises: RNA polymerase variants, buffer components, modified or unmodified nucleoside triphosphates, RNase inhibitors, pyrophosphatase, magnesium ions, water, and cap analogs. In some embodiments, the in vitro transcription reaction composition described in the present application comprises: RNA polymerase variants, buffer components, modified or unmodified nucleoside triphosphates, RNase inhibitors, pyrophosphatase, magnesium ions, water, cap analogs, and DNA templates.

[0047] Reagent test kit

[0048] The present application provides a kit, which comprises at least one RNA polymerase variant described in the present application.

[0049] In some embodiments, the kit may further comprise one or more in vitro transcription reaction reagents (e.g., buffer components, modified or unmodified nucleoside triphosphates, RNase inhibitors, pyrophosphatase, magnesium ions, water, etc.). In some embodiments, the kit further comprises a cap analog. In some embodiments, each component in the kit (if applicable) may be provided in liquid form (e.g., in solution) or in solid form (e.g., dry powder).

[0050] The kits described herein may include one or more containers containing one or more components described herein and optionally instructions for use.

[0051] Application or use

[0052] The present application provides the use of the above-mentioned RNA polymerase variants, compositions, or kits in in vitro transcription.

[0053] The present application also provides the use of the above-mentioned RNA polymerase variants, compositions, or kits in various methods, including but not limited to the preparation of RNA, the preparation of RNA probes, the preparation of RNA vaccines, the preparation of proteins, etc.

[0054] Methods for preparing RNA

[0055] The present application provides a method for preparing RNA. In some embodiments, the method comprises contacting a DNA template, a modified or unmodified nucleoside triphosphate with at least one RNA polymerase variant described in the present application, incubating in an in vitro transcription reaction system, and obtaining a target RNA product. In some embodiments, the RNA product may be dsRNA, ssRNA, mRNA, siRNA, miRNA, piRNA, shRNA, or gRNA.

[0056] The present application also provides a method for preparing capped mRNA. In some embodiments, the method comprises contacting a DNA template, modified or unmodified nucleoside triphosphates, and a cap analog with at least one RNA polymerase variant described in the present application, and incubating them in an in vitro transcription reaction system to obtain a target product.

[0057] In vitro transcription reaction systems and incubation conditions suitable for generating RNA products or capped mRNA products are well known in the art. A person of ordinary skill in the art can determine the appropriate pH value, reaction temperature, reaction time, salt concentration, or whether to add exogenous auxiliary factors, etc. of the reaction system, taking into account the optimal activity of RNA polymerase. In some embodiments, the in vitro transcription reaction system described in the present application comprises in vitro transcription reaction reagents: one or more buffer components, modified or unmodified nucleoside triphosphates, RNase inhibitors, pyrophosphatase, magnesium ions, water, etc. In some embodiments, in the incubation step described in the present application, the incubation temperature is 30-50°C, preferably 37°C. In some embodiments, in the incubation step described in the present application, the incubation time is 20-240 min, preferably 60 min.

[0058] In some embodiments, the RNA product or capped mRNA product prepared using the method described in the present application has a higher yield, and / or higher integrity, and / or has less dsRNA impurity content, and / or more capped mRNA products, etc. compared to using a wild-type RNA polymerase.

[0059] In some embodiments, the capped mRNA product prepared by the method described in the present application can improve the utilization rate of the cap analog compared to using a wild-type RNA polymerase, wherein the capping rate of the obtained mRNA product can be increased to at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.

[0060] Hat analogs

[0061] The cap analog used in the method for preparing a capped mRNA product or the cap analog in an in vitro transcription reaction composition described in the present application refers to a molecule that can be complementary to a nucleotide molecule on a DNA template at the transcription start site.

[0062] In some embodiments, the cap analog can be selected from a dinucleotide cap, a trinucleotide cap or a tetranucleotide cap. In some embodiments, the cap analog is a trinucleotide cap, which can be selected from GAA, GAC, GAG, GAU, GCA, GCC, GCG, GCU, GGA, GGC, GGG, GGU, GUA, GUC, GUG and GUU. In some embodiments, the trinucleotide cap can be selected from m7GpppApA, m7GpppApC, m7GpppApG, m7GpppApU, m7GpppCpA, m7GpppCpC, m7GpppCpG, m7GpppCpU, m7GpppGpA, m7GpppGpC, m7GpppGpG, m7GpppGpU, m7GpppUpA, m7GpppUpC, m7GpppUpG, and m7GpppUpU. In some embodiments, the trinucleotide cap can be selected from m7G3′OMepppApA, m7G3′OMepppApC, m7G3′OMepppApG, m7G3′OMepppApU, m7G3′OMepppCpA, m7G3′OMepppCpC, m7G3′OMepppCpG, m7G3′OMepppCpU, m7G3′OMepppGpA, m7G3′OMepppGpC, m7G3′OMepppGpG, m7G3′OMepppGpU, m7G3′OMepppUpA, m7G3′OMepppUpC, m7G3′OMepppUpG, and m7G3′OMepppUpU. In some embodiments, the trinucleotide cap may be selected from m7G3′OMepppA2′OMepA, m7G3′OMepppA2′OMepC, m7G3′OMepppA2′OMepG, m7G3′OMepppA2′OMepU, m7G3′OMepppC2′OMepA, m7G3′OMepppC2′OMepC, m7G3′OMepppC2′OMepG, m7G3′OMeppp C2′OMepU, m7G3′OMepppG2′OMepA, m7G3′OMepppG2′OMepC, m7G3′OMepppG2′OMepG, m7G3′OMepppG2′OMepU, m7G3′OMepppU2′OMepA, m7G3′OMepppU2′OMepC, m7G3′OMepppU2′OMepG, and m7G3′OMepppU2′OMepU.In some embodiments, the trinucleotide cap can be selected from m7GpppA2′OMepA, m7GpppA2′OMepC, m7GpppA2′OMepG, m7GpppA2′OMepU, m7GpppC2′OMepA, m7GpppC2′OMepC, m7GpppC2′OMepG, m7GpppC2′OMepU, m7GpppG2′OMepA, m7GpppG2′OMepC, m7GpppG2′OMepG, m7GpppG2′OMepU, m7GpppU2′OMepA, m7GpppU2′OMepC, m7GpppU2′OMepG, and m7GpppU2′OMepU.

[0063] In some embodiments, the cap analog described herein is preferably m7GpppA2′OMepG.

[0064] In some embodiments, when a trinucleotide cap GAG (such as m7GpppA2′OMepG) is used to prepare a capped mRNA product, or in an in vitro transcription reaction composition containing the cap analog, the first nucleotide at the +1 position of the DNA template molecule (sense strand) is G, and the second nucleotide at the +2 position is G. In some embodiments, the nucleotide residues in the m7GpppA2′OMepG cap analog can complementarily pair with the +1 position of the antisense strand of the DNA template molecule (such as Figure 2 ).

[0065] In vitro transcription reaction reagents

[0066] The in vitro transcription reaction reagents described in the present application include buffer components, nucleoside triphosphates, RNase inhibitors, inorganic pyrophosphatase, magnesium ions, water (such as DEPC-water, RNase-free water, DNase-free water, sterile purified water, deionized water, distilled water, etc.), etc.

[0067] In some embodiments, the buffer component can be selected from one or more of: phosphate buffer, Tris buffer, MOPS buffer, HEPES buffer, citrate buffer, acetate buffer, malic acid buffer, MES buffer, histidine buffer, PIPES buffer, bis-tris buffer and ethanolamine buffer.

[0068] In some embodiments, the nucleoside triphosphates can be selected from modified or unmodified nucleoside triphosphates (including analogs thereof). In some embodiments, the nucleoside triphosphates can be selected from unmodified ATP, GTP, CTP, UTP. In some embodiments, the nucleoside triphosphates can be selected from modified nucleoside triphosphates, and the modification types on the nucleoside include but are not limited to m1A (N1-methyladenosine), m6A (N6-methyladenosine), m5C (5-methylcytidine), 5moU (5-methoxyuridine), ψ (pseudouridine), m1ψ (N1-methyl-pseudouridine), nucleoside triphosphates with markers (the markers can be biotin, fluorescent substances, digoxin, radioactive elements, etc.).

[0069] In some embodiments, the in vitro transcription reaction reagents described herein can be selected from any commercially available RNA in vitro transcription reagent.

[0070] Other implementations: 1. An RNA polymerase variant, whose amino acid sequence, relative to SEQ ID NO: 1, comprises at least one substitution or deletion of the following amino acid positions: R34, K172, Y178, R386, D388, Q435, N437, D438.

[0071] 2. A variant as described in item 1, wherein: (1) the substitution at position R386 is selected from C or W; (2) The substitution at position D388 is K; (3) the substitution at position Q435 is selected from A, H, and T; (4) the substitution at position N437 is selected from F and T; (5) the substitution at position D438 is selected from T, L, I, P, V; (6) the substitution at position R34 is selected from A; (7) The mutation at position K172 is a deletion; (8) The substitution at position Y178 is selected from H and D.

[0072] 3. The variant as described in the first item, whose amino acid sequence comprises any mutation selected from the following sites relative to SEQ ID NO: 1: R386W, R386C, D388K, Q435A, Q435H, Q435T, N437F, N437T, D438T, D438L, D438I, D438P, D438V, R386A+R34A, R386M+R34A, R386M+Y178H, R386W+N437T, R386I+del-K172, R386F+Y178D, D388K+D438P, R386C+D438P.

[0073] 4. The variant as described in item 1, wherein the amino acid sequence of the variant is shown in any one of SEQ ID NOs: 2-22.

[0074] 5. A polynucleotide molecule encoding a variant as described in any one of items 1 to 4.

[0075] 6. An expression vector comprising the polynucleotide molecule as described in item 5.

[0076] 7. A host cell comprising the polynucleotide molecule as described in item 5, or the expression vector as described in item 6.

[0077] 8. A method for preparing a variant as described in any one of items 1 to 4, comprising: (1) cultivating the host cell as described in item 7; and (2) Recycling variants.

[0078] 9. A composition comprising the variant as described in any one of items 1 to 4.

[0079] 10. The composition as described in item 9, further comprising a cap analog.

[0080] 11. The composition as described in item 9 or 10, further comprising a DNA template.

[0081] 12. A kit comprising the variant as described in any one of items 1 to 4.

[0082] 13. Use of the variant described in any one of items 1 to 4, the composition described in any one of items 9 to 11, or the kit described in item 12 in in vitro transcription.

[0083] 14. A method for preparing RNA, comprising contacting a DNA template, modified or unmodified nucleoside triphosphates with the RNA polymerase variant described in any one of items 1 to 4, and incubating them in an in vitro transcription reaction system to obtain a target RNA product.

[0084] 15. A method for preparing capped mRNA, comprising contacting a DNA template, modified or unmodified nucleoside triphosphates, and a cap analog with the RNA polymerase variant described in any one of items 1 to 4, and incubating them in an in vitro transcription reaction system to obtain a target product.

[0085] 16. The method as described in item 15, wherein the cap analog is a trinucleotide cap, preferably m7GpppA2′OMepG.

[0086] 17. In the composition as described in item 11 or the method as described in any one of items 14 to 16, the DNA template has 2'-deoxyguanosine residues at positions +1 and +2.

[0087] 18. Use of the variant of any one of items 1 to 4, the composition of any one of items 9 to 11, or the kit of claim 12 in the transcription of a DNA template having 2'-deoxyguanosine residues at template positions +1 and +2.

[0088] Beneficial Effects

[0089] The present application provides a class of RNA polymerase variants and a preparation method thereof. By modifying the wild-type T7 RNA polymerase, an RNA polymerase variant with higher catalytic efficiency is obtained. By using such variants, the capping rate of mRNA products during in vitro transcription can be increased, and more capped mRNA products can be obtained. In addition, the present application also provides a method for preparing capped mRNA, which can increase the yield of capped mRNA products and reduce the amount of cap analogs, thereby avoiding the waste of raw materials and saving production costs, which is of great significance for the economical production of RNA. BRIEF DESCRIPTION OF THE DRAWINGS

[0090] Figure 1 is a schematic diagram of a double-stranded DNA template; Figure 2 for the complementary pairing of the cap analog and the DNA template; Figure 3 Schematic diagram of the construction of recombinant plasmid; Figure 4 for the effects of RNA polymerase and its variants (R386W, Q435A, Q435H, Q435T, N437F, N437T, D438T, D438L, D438I, D438P, D438V, R386A+R34A, R386M+R34A, R386M+Y178H, R386W+N437T, R386I+Del172, R386F+Y178D) on mRNA capping rates; Figure 5 The effects of RNA polymerase and its variants (WT, R386C, R386W, D388K, R386C+D438P, R386W+N437T, D388K+D438P, N437T, D438P) on mRNA capping rate. DETAILED DESCRIPTION

[0091] In the present application, the unit enzyme activity (U) is defined as the amount of enzyme activity that can be activated within 1 hour at 37°C and pH 8.0 to produce 1 nmol [ 3The amount of enzyme required to incorporate [H]ATP into the acid-insoluble precipitate was defined as 1 unit of activity.

[0092] Example 1 Preparation of RNA polymerase variants

[0093] The RNA polymerases shown in Tables 1-1 to 1-6 were synthesized by DNA sequence (SEQ ID NO: 23-44) and then amplified by PCR. Then, the recombinant expression vector was obtained by introducing the BseRI and HindIII restriction sites of the expression vector pQE-80L. The constructed vector was introduced into E. coli BL21 (DE3), spread on LB plates containing ampicillin resistance, put in a 37°C incubator overnight, extract and sequence the single colonies that grew, and finally obtain recombinant engineered bacteria containing the target gene. E. coli The recombinant strain was inoculated into LB medium for overnight activation culture and then inoculated into fermentation broth (LB medium) at 1% V / V and cultured until the OD600 value was 0.6-0.8. IPTG with a final concentration of 0.5 mol / L was added and cultured for 4-6 h. The strain was collected by centrifugation at 12000 rpm and 4°C, and the collected strain was washed with PBS buffer with a pH value of 7.0 and 0.2 M to obtain the bacteria. After ultrasonic disruption, affinity chromatography was performed for purification to obtain RNA polymerase stock solution.

[0094] The correspondence between RNA polymerase variants and amino acid sequences is shown in Tables 1-1 to 1-6: Table 1-1:

[0095] Table 1-2:

[0096] Table 1-3:

[0097] Table 1-4:

[0098] Table 1-5:

[0099] Table 1-6:

[0100] Example 2 Preparation of mRNA by in vitro transcription reaction

[0101] The enzyme stock solution was diluted with storage buffer (50 mM Tris-HCl (25℃, pH 7.9), 100 mM NaCl, 0.1 mM EDTA, 2 mM DTT, 0.1% Triton X-100, 50% Glycerol) to an enzyme activity of 400 U / μL. MIX solution was prepared according to the reaction system (20 μL) in Table 2 and put into EP tubes. The MIX solution was transferred to eight strips, mixed and centrifuged; the eight strips were placed on a PCR instrument and reacted at 37℃ for 1 h, and then 36 μL of magnetic beads (Vazyme, catalog number: N412) were added and mixed and incubated at room temperature for 2-5 minutes; the mixed solution was placed on a magnetic stand to purify mRNA, and after purification, it was transferred to an RNase-free centrifuge tube to obtain purified mRNA.

[0102] Table 2: Reaction system ratio

[0103] Example 3 Capping rate detection

[0104] After pre-treatment with the mRNA Capping Rate Detection Kit (Vazyme, Catalog No.: DD3510-01), the capping rate of the mRNA product was detected by LC-MS: (1) The purified mRNA in Example 2 was combined with the probe. The reaction system is shown in Table 3, and the reaction conditions are shown in Table 4; Table 3: Reaction system

[0105] Table 4: Reaction conditions

[0106] (2) RNase H digestion: Prepare the digestion system according to Table 5, vortex thoroughly to mix well, and place in a PCR instrument for reaction at 25°C for 20 min. Table 5: Reaction system

[0107] (3) SA magnetic bead binding: ① Magnetic bead washing: Take 9 μL SA magnetic beads (Cat. No.: SM017005) into a centrifuge tube and place it on a magnetic rack. When the solution becomes clear, use a pipette to discard the supernatant. Remove the centrifuge tube from the magnetic rack, add 200 μL RNase-free H2O to rinse, place it on a magnetic rack, when the solution becomes clear, use a pipette to discard the supernatant, and then add 200 μL RNase-free H2O to repeat the rinse.

[0108] ② Reaction conditions: Remove the centrifuge tube from the magnetic rack, add the enzyme cleavage product to the SA magnetic beads (solid), pipette 20-30 times, mix thoroughly, place on a tumbling instrument and incubate at room temperature for 30 minutes to allow the magnetic beads and the enzyme cleavage product to fully combine.

[0109] (4) Rinse and wash: ① Place the product from the previous step on a magnetic rack for 2-3 min until the solution becomes clear and discard the supernatant with a pipette; ② Add 200 μL of rinsing solution to rinse, taking care to avoid blowing away the magnetic beads, let it stand for 0.5-1 min, and discard the supernatant with a pipette; ③Repeat step ②; ④ Remove the centrifuge tube from the magnetic stand, add 30 uL of elution buffer, and mix well by pipetting 10-20 times to make the magnetic beads evenly dispersed and fully eluted; ⑤ Place in a PCR instrument, react at 85℃ for 3 min, then immediately place on a magnetic rack. After the solution is clarified (0.5-1 min), pipette the supernatant into a new centrifuge tube. The supernatant is the desired product. ⑥ The above product was sent to Thermo scientific Vanquish Flex-Qrbitrap Exploris120 to detect the capping rate (mobile phase: phase A: 2% hexafluoroisopropanol-1% N'N-diisopropylethylamine aqueous solution, phase B: 2% hexafluoroisopropanol-1% N'N-diisopropylethylamine methanol solution; chromatographic column: Nano ChromCore C18 3μm, 4.6*100mm;; ion mode: negative ion; scanning mode: Full scan; scanning range: 600-3000), capping rate calculation formula: mRNA capping rate (%) = (capped mRNA / (capped mRNA + uncapped mRNA)) ×100%.

[0110] Test results see Figure 4 When the ratio of cap analog to raw material NTP is as low as 0.33:1, the T7 RNA polymerase variants in Example 1 can well improve the capping rate of mRNA products, and R386W+N437T increases the capping rate to 100%.

[0111] Example 4 Preparation of mRNA by in vitro transcription reaction

[0112] The mRNA in vitro transcription preparation was performed with reference to Example 2, and the amount of cap analog added was further reduced to 0.24 μL (as shown in Table 6), the other reaction conditions were the same, and the capping rate was further detected with reference to Example 3.

[0113] Table 6: Reaction system ratio

[0114] The results are as follows Figure 5 As shown in the figure, relative to the wild-type T7 RNAP, all mutation sites effectively increased the capping rate, among which the T7 RNAP superimposed mutations R386C+D438P, R386W+N437T, and D388K+D438P all significantly increased the capping rate on the basis of the single site, among which the capping rate of D388K+D438P increased to 95.5% relative to the 84% capping rate of the single site D388K and the 68.5% capping rate of D438P, with an increase of >10%.

Claims

1. An RNA polymerase variant, characterized in that The amino acid sequence of the variant comprises, relative to SEQ ID NO: 1, at least one substitution or deletion of an amino acid position selected from the group consisting of R34, K172, Y178, R386, D388, Q435, N437, and D438.

2. A variant according to claim 1, characterized in that in: (1) the substitution at position R386 is selected from C or W; (2) The substitution at position D388 is K; (3) the substitution at position Q435 is selected from A, H, and T; (4) the substitution at position N437 is selected from F and T; (5) the substitution at position D438 is selected from T, L, I, P, V; (6) the substitution at position R34 is selected from A; (7) The mutation at position K172 is a deletion; (8) The substitution at position Y178 is selected from H and D.

3. The variant according to claim 1, characterized in that The amino acid sequence of the variant comprises any mutation selected from the following sites relative to SEQ ID NO: 1: R386W, R386C, D388K, Q435A, Q435H, Q435T, N437F, N437T, D438T, D438L, D438I, D438P, D438V, R386A+R34A, R386M+R34A, R386M+Y178H, R386W+N437T, R386I+del-K172, R386F+Y178D, D388K+D438P, R386C+D438P.

4. The variant according to claim 1, characterized in that The amino acid sequence of the variant is shown in any one of SEQ ID NOs: 2-22.

5. A polynucleotide molecule, characterized in that The polynucleotide molecule encodes the variant according to any one of claims 1-4.

6. An expression vector, characterized in that Comprising the polynucleotide molecule as claimed in claim 5.

7. A host cell, characterized in that Comprising the polynucleotide molecule as claimed in claim 5 or the expression vector as claimed in claim 6.

8. A method for preparing a variant according to any one of claims 1 to 4, characterized in that: include: (1) culturing the host cell according to claim 7; and (2) Recycling variants.

9. A composition, characterized in that The composition comprises the variant according to any one of claims 1-4.

10. A kit, characterized in that The kit comprises the variant according to any one of claims 1-4.

11. Use of the variant according to any one of claims 1 to 4, the composition according to claim 9, or the kit according to claim 10 in in vitro transcription.

12. A method for preparing RNA, characterized in that: The method comprises contacting a DNA template, modified or unmodified nucleoside triphosphates with the RNA polymerase variant described in any one of claims 1 to 4, and incubating them in an in vitro transcription reaction system to obtain a target RNA product.

13. A method for preparing capped mRNA, characterized in that: The method comprises contacting a DNA template, modified or unmodified nucleoside triphosphates, a cap analog and the RNA polymerase variant described in any one of claims 1 to 4, incubating them in an in vitro transcription reaction system, and obtaining a target product.

14. The method as claimed in claim 13, characterized in that The cap analog is a trinucleotide cap.

15. The method according to claim 14, characterized in that The trinucleotide cap is m7GpppA2′OMepG.

16. The method according to any one of claims 12 to 15, characterized in that: Positions +1 and +2 of the DNA template are 2'-deoxyguanosine residues.

17. Use of the variant of any one of claims 1 to 4, the composition of claim 9, or the kit of claim 10 in the transcription of a DNA template having 2'-deoxyguanosine residues at template positions +1 and +2.

Citation Information

Patent Citations

  • RNA polymerase variants

    CN111212905A

  • Enzymatic RNA capping method

    CN112714795A

  • RNA polymerase variant, and preparation method therefor and use thereof in RNA synthesis

    WO2024131998A2

Cited By

  • RNA polymerase variants and uses thereof

    CN120330158A

  • RNA polymerase variants and uses thereof

    CN120505294A

  • RNA polymerase variants and their applications

    CN120505294B

  • RNA polymerase variants and uses thereof

    CN121294389A

  • RNA polymerase variants and uses thereof

    CN121555463A